Company intelligence / Profile preview

Milky Way BioPharma

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

Intellectual property covering monoclonal antibodies targeting integrin αvβ6 and αvβ8 was licensed to Corbus Pharmaceuticals for fibrosis; as of July 2024, the license agreement has been terminated and the program discontinued under Milky Way BioPharma

Therapeutic areas: Other
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Corbus Pharmaceuticals (license agreement for CRB-602/anti-integrin mAb program)

Beyond the preview

Go deeper on Milky Way BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Milky Way BioPharma.

Explore the full profile